Invest now
Nectar Lifesciences share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹10.55(4.98%)October 16, 2026 15:11:31 PM IST
- NSE
- BSE
- Vol : 188.13 K (NSE + BSE)Last 20 day avg : 153.37 K
Nectar Lifesciences is trading 4.98% upper at Rs 10.55 as compared to its last closing price. Nectar Lifesciences has been trading in the price range of 10.55 & 10.01. Nectar Lifesciences has given -48.27% in this year & -4.83% in the last 5 days. Nectar Lifesciences has TTM P/E ratio 1.10 as compared to the sector P/E of 33.15.The company posted a net profit of -15.40 Crores in its last quarter.Listed peers of Nectar Lifesciences include Sun Pharmaceutical Industries (-0.03%), Divi's Laboratories (1.99%), Torrent Pharmaceuticals (-1.00%).The Mutual Fund holding in Nectar Lifesciences was at -% in . The MF holding has - from the last quarter. The FII holding in Nectar Lifesciences was at 0.50% in 30 Sep 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 17 Oct 2026, 03:24 AM IST
- BetaHigh volatility1.57Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Nectar Lifesciences Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,760.00 | -0.03 | 4,22,273.00 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,220.00 | 1.99 | 2,44,762.03 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,560.00 | -1.00 | 1,73,441.54 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,325.00 | -0.65 | 1,07,041.24 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,124.30 | -1.44 | 1,12,149.36 | 21.19 | 4.24 | 0.09 | 14.22 |
Nectar Lifesciences Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-14 | Quarterly Results |
| 2026-05-30 | Audited Results |
| 2026-01-23 | Quarterly Results & Others |
| 2025-11-14 | Quarterly Results |
| 2025-08-14 | Quarterly Results & Others |
About the company Nectar Lifesciences
- IndustryBiotechnology & Drugs
- ISININE023H01027
- BSE Code532649
- NSE CodeNECLIFE
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Nectar Lifesciences Share Price FAQs
Nectar Lifesciences is trading at 10.55 as on Fri Oct 16 2026 09:41:31. This is 4.98% upper as compared to its previous closing price of 10.05.
The market capitalization of Nectar Lifesciences is 204.57 Cr as on Fri Oct 16 2026 09:41:31.
The 52 wk high for Nectar Lifesciences is 22.49 whereas the 52 wk low is 9.20
Nectar Lifesciences can be analyzed on the following key metrics -
- TTM P/E: 1.10
- Sector P/E: 33.15
- Dividend Yield: 0.00%
- D/E ratio: -
Nectar Lifesciences reported a net profit of -292.89 Cr in 2026.
Quick Links
EQUITY QUICK LINKS
Nectar Lifesciences QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.